Monitor for actual sales under this ATM program, as the filing itself is procedural. The small offering size suggests a need for capital but is not immediately dilutive unless fully utilized.
INM drugs
INM drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 6 $0.6950entry
- T+1 · 7mo ago −2.16%α −2.22% · $0.6800
- T+5 · 7mo ago +2.59%α −1.54% · $0.7130
- T+20 · 7mo ago +7.63%α −1.36% · $0.7480
- T+60 · 5mo ago +128.78%α +115.31% · $1.59
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
InMed Pharmaceuticals filed a prospectus supplement to its shelf registration statement to sell up to $1,213,648 worth of common shares through an at-the-market offering with H.C. Wainwright & Co. This is a routine capital raise under an existing agreement.
Key Facts
- InMed Pharmaceuticals filed a prospectus supplement on April 3, 2026, to sell up to $1,213,648 of common shares.
- The offering is conducted through an at-the-market (ATM) agreement with H.C. Wainwright & Co., originally dated April 7, 2022, and amended June 27, 2024.
- The shares are being offered under a shelf registration statement (Form S-3, File No. 333-294503) declared effective on March 30, 2026.
- The filing includes a legal opinion confirming the legality of the securities being registered.
Financial Impact
Up to $1,213,648 in gross proceeds from the sale of common shares, representing a small potential dilution given the company's $2M market cap.
Risk Factors
- Potential share dilution if the full amount is sold.
- Downward pressure on stock price if sales occur in a weak market.
- Use of proceeds not specified, creating uncertainty about how funds will be deployed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-039943 |
| Document: ea028498901ex5-1.htm | 0001213900-26-039943 |
| Document: 0001213900-26-039943-index-headers.html | 0001213900-26-039943 |
| Document: 0001213900-26-039943-index.html | 0001213900-26-039943 |
| Document: 0001213900-26-039943.txt | 0001213900-26-039943 |
Track record
22 reports on INM
6 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +24.51% at T+1 after the Nov 3, 2026 report. 10 of 12 went positive at some point.
Filters
- Nov 9, 20267d ago 8-K Neutral 5/10 Entry $16.00 Now $19.87 +24.19% settles Dec 8
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $13.21 Now $19.87 +50.42% settles Dec 4
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $13.21 Now $19.87 +50.42% settles Dec 4
- Nov 3, 202613d ago 8-K Bearish 6/10 Entry $1.75 Now $19.87 −1035.43% settles Dec 3
- Nov 2, 202614d ago 425 Neutral 3/10 Entry $1.68 Now $19.87 +1082.74% settles Dec 2
- Oct 26, 202621d ago 425 Neutral 3/10 Entry $1.59 Now $19.87 +1149.69% settles Nov 24
- Oct 7, 20265w ago SC 13G/A Bullish 5/10 Entry $1.33 to $1.32 Now $19.87 +1393.99% ▼ −0.68% +4.61% vs SPY
- Oct 2, 20266w ago EFFECT Neutral 3/10 Entry $1.33 to $1.60 Now $19.87 +1393.99% ▲ +20.30% +22.11% vs SPY
- Sep 18, 20268w ago 8-K Bearish 6/10 Entry $1.38 to $1.37 Now $19.87 −1339.86% ▲ +1.06% +0.15% vs SPY
- Sep 9, 20269w ago 425 Neutral 6/10 Entry $1.31 to $1.33 Now $19.87 +1416.79% ▲ +1.53% −0.60% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers